報價延遲最少15分鐘:2026/02/25 05:38 EST
盤前時段
|
||||
|
8.39 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.28
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.83/-0.42
|
|
企業價值
770.18M
|
| 資產負債 |
|
每股賬面淨值
1.93
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
73.48M
|
|
每股收益
0.79
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
